Welcome!
hina Resources Pharmaceutical Group
Broker's Calls
PhillipCapital 'remains confident' in iX Biopharma’s growth prospects upon China agreement
PhillipCapital has kept its "buy" recommendation with the same target price of 44.5 cents.
April 08, 2021